Clopidogrel tab 75mg
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Clopidogrel 75 mg Tablet: Efficacy, Dosage, and Pharmacokinetics
Bioequivalence of Clopidogrel 75 mg Tablets
Bioequivalence Studies
A study aimed to assess the bioequivalence of two formulations of 75 mg clopidogrel hydrogen sulphate film-coated tablets under fasting conditions. The study involved 64 healthy subjects in a randomized, single-dose, open-label, 2-way crossover design. The pharmacokinetic parameters, AUClast and Cmax, were used for bioequivalence assessment. The results showed that the 90% confidence intervals for both analytes were within the predefined ranges (80.00 - 125.00%), indicating bioequivalence in terms of rate and extent of absorption.
Comparative Efficacy of Clopidogrel Dosages
Antiplatelet and Anti-inflammatory Effects
In patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), a study compared the antiplatelet effect of a 75 mg daily maintenance dose of clopidogrel with a 150 mg dose. The results indicated that the 150 mg dose significantly reduced platelet reactivity and C-reactive protein levels compared to the 75 mg dose, suggesting a more potent antiplatelet and anti-inflammatory effect.
Platelet Aggregation Inhibition
Another study evaluated whether increasing the clopidogrel maintenance dose to 150 mg would result in greater inhibition of platelet aggregation compared to the standard 75 mg dose. The study found that the 150 mg dose led to significantly lower platelet aggregation levels, as measured by optical aggregometry and the VerifyNow P2Y12 assay, indicating more intense inhibition of platelet aggregation.
Pharmacokinetics of Clopidogrel
Absorption and Metabolism
Clopidogrel is extensively metabolized, with the major circulating compound being the inactive carboxylic acid derivative SR26334. A study on the pharmacokinetics of SR26334 showed dose-proportional increases in Cmax across single doses of 50, 75, 100, and 150 mg. The urinary excretion of SR26334 was low, and the pharmacokinetic parameters such as Tmax and plasma half-life remained consistent across different doses. Repeated dosing with 75 mg daily showed steady-state values similar to those observed during long-term administration, indicating consistent biotransformation over time.
Loading Dose Regimens
Rapid Onset of Action
Studies have shown that a loading dose of clopidogrel, followed by daily doses of 75 mg, can achieve a sustained steady-state level of platelet inhibition. For instance, a 375 mg loading dose followed by 75 mg daily resulted in significant inhibition of platelet aggregation within hours, reaching a maximum of 80% inhibition at 5 hours. This rapid onset of action suggests that higher initial doses can quickly achieve therapeutic levels of platelet inhibition.
Clinical Implications and Safety
Efficacy in Reducing Vascular Events
Clopidogrel 75 mg/day has been shown to be effective in reducing the risk of atherosclerotic events such as myocardial infarction, ischemic stroke, and vascular death. In the CAPRIE study, clopidogrel was more effective than aspirin in preventing these events, with a better gastrointestinal tolerability profile. Additionally, in a large randomized trial involving patients with acute myocardial infarction, adding clopidogrel 75 mg to aspirin significantly reduced mortality and major vascular events without increasing the risk of serious bleeding.
Conclusion
Clopidogrel 75 mg tablets are bioequivalent to other formulations and effective in reducing platelet aggregation and preventing atherosclerotic events. Higher doses, such as 150 mg, may offer enhanced antiplatelet effects but come with an increased risk of minor bleeding. The pharmacokinetics of clopidogrel indicate consistent absorption and metabolism, making it a reliable option for long-term use in preventing thrombotic events.
Sources and full results
Most relevant research papers on this topic